Drug Approvals, Study Results, and Clinical Collaborations for Top-Line Growth - Research Report on Pfizer, Merck & Co., Cubist,

Drug Approvals, Study Results, and Clinical Collaborations for Top-Line Growth
   - Research Report on Pfizer, Merck & Co., Cubist, AstraZeneca and Impax

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, July 23, 2013

NEW YORK, July 23, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Cubist Pharmaceuticals Inc.
(NASDAQ: CBST), AstraZeneca PLC (NYSE: AZN) and Impax Laboratories Inc.
(NASDAQ: IPXL). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Pfizer Inc. Research Report

On July 15, 2013, Pfizer Inc. (Pfizer) announced that tofacitinib has been
approved for the treatment of rheumatoid arthritis (RA) in patients who had an
inadequate response to existing therapies in several additional countries
including Switzerland, Argentina, Kuwait and UAE. Pfizer stated that
Swissmedic, the Swiss agency for therapeutic products, approved tofacitinib as
monotherapy or in combination with a disease modifying non-biologic
antirheumatic agent, including methotrexate (MTX), in adult patients with
moderate-to-severe active RA, who have had an inadequate response or
intolerance to MTX. "More than 23 million people worldwide are living with
rheumatoid arthritis and there remains an unmet need for additional
treatments, with up to one-third of RA patients not adequately responding and
about half who stop responding to any particular DMARD within five years,"
said Geno Germano, President and General Manager, Specialty Care and Oncology,
Pfizer. "XELJANZ has a novel mechanism of action for the treatment of
moderate-to-severe RA. With these approvals, we believe XELJANZ has the
potential to change the way rheumatologists treat this chronic, and
potentially disabling, disease, and we are proud to offer patients and
physicians an additional treatment option." The Full Research Report on Pfizer
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

Merck & Co. Inc. Research Report

On July 14, 2013, Merck & Co. inc. (Merck) announced results from a Phase Ib
study in patients with mild to moderate Alzheimer's disease (AD). In the
study, β amyloid levels were analyzed as a measure of BACE (β-site amyloid
precursor protein cleaving enzyme) activity. The study showed a dose-dependent
decrease in β amyloid levels in cerebral spinal fluid (CSF) following
administration of MK-8931, Merck's investigational oral β-site amyloid
precursor protein cleaving enzyme (BACE1 or β secretase) inhibitor. "The
amyloid β reduction observed with MK-8931 may offer an opportunity to further
understand the role BACE1 inhibition plays in the underlying pathology of
Alzheimer's disease," said Darryle Schoepp, Ph.D., Vice President of
Neuroscience Early Development and Discovery Sciences, Merck. "Further
evaluation of MK-8931 continues in our EPOCH study, a Phase II/III trial in
patients with mild to moderate Alzheimer's." The Full Research Report on Merck
& Co. Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

Cubist Pharmaceuticals Inc. Research Report

On July 18, 2013, Cubist Pharmaceuticals Inc. (Cubist) announced its Q2 2013
financial results. The Company reported total net revenues of $258.8 million,
an increase of 12.2% YoY. Its non-GAAP adjusted operating income was $51.3
million compared to $71.1 million in Q2 2012. Non-GAAP diluted EPS was $0.42
compared to $0.56 in the Q2 2012. "We made important progress across the
company this quarter, highlighted by continued strong top-line growth and
advancement of our exciting late-stage pipeline," said Michael Bonney, Chief
Executive Officer of Cubist. "We are pleased to have now secured Fast-Track
status from the FDA for ceftolozane/tazobactam in all three of its potential
indications, and we look forward to reporting top-line Phase 3 data from the
cUTI and cIAI trials later this year. We are making progress against our
Building Blocks of Growth goals and continue to enhance our leadership in the
acute care environment." The Full Research Report on Cubist Pharmaceuticals
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

AstraZeneca PLC Research Report

On July 9, 2013, AstraZeneca Plc. (AstraZeneca) announced that it has signed
an agreement with the University of Cambridge and Cancer Research UK for a
two-year collaboration on three pre-clinical and clinical oncology projects.
The collaboration aims to advance cancer research through the study of tumour
mutations and new investigational therapies in prostate, pancreatic and
potentially other cancers. "These are the first research collaborations
AstraZeneca has established with Cambridge-based partners since announcing our
intention to build a strategic research and development centre on the
Cambridge Biomedical Campus," said Susan Galbraith, Head of AstraZeneca's
Oncology Innovative Medicines Unit. "It is fitting that the focus of these
collaborations is on delivering new medicines for cancer because our Cambridge
facility will become AstraZeneca's largest centre for oncology research." The
Full Research Report on AstraZeneca PLC - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/09cc_AZN]

Impax Laboratories Inc.Research Report

On July 15, 2013, Impax Laboratories Inc. (Impax) announced the commencement
of shipment of authorized generic TRILIPIX (fenofibric acid) delayed release
capsules, 45 mg and 135 mg, through Global Pharmaceuticals, Impax's generics
division. Under the terms of a settlement agreement, Abbott Laboratories, now
AbbVie Inc., and Fournier Laboratories Ireland Ltd. granted Impax the right to
sell an authorized generic as early as July 15, 2013. The Full Research Report
on Impax Laboratories Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:


1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.


SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.